Physician profile

Michael Knee

Midland Park, NJ

NPI 1225123961

$19,938.45

in general payments reported to CMS, 2019-2025

43 companies · $2,772 in 2025

The $2,772 reported for 2025 was more than what 96% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$8,343.53
Education$99.80

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $3,518.84 2019-2025 Evenity, Krystexxa, Enbrel
Abbvie INC. $2,883.79 2019-2025
Novartis Pharmaceuticals Corporation $1,567.82 2019-2025
Mallinckrodt Hospital Products INC. $1,291.28 2020-2025 Acthar
Astrazeneca Pharmaceuticals Lp $1,227.46 2021-2025 Saphnelo
Lilly USA, LLC $1,195.33 2019-2024 Taltz, Olumiant
Pfizer INC. $921.92 2019-2025
Janssen Biotech, INC. $853.59 2019-2025 Tremfya, Simponi Aria, Simponi
Ucb, INC. $715.95 2019-2025 Cimzia, Bimzelx
Genzyme Corporation $670.29 2019-2025
Aurinia Pharma U.S., INC. $576.35 2021-2025 Lupkynis
Horizon Therapeutics Plc $573.81 2019-2023 Krystexxa
Glaxosmithkline, LLC. $535.04 2019-2024 Benlysta, Nucala
Genentech USA, INC. $432.03 2019-2023 Actemra
Radius Health, INC. $378.59 2019-2025 Tymlos
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Janssen Scientific Affairs, LLC $353.55 2019-2022
Medexus Pharma, INC. $301.23 2019-2020
Collegium Pharmaceutical, INC. $291.41 2021-2025 Xtampza, Belbuca
Alexion Pharmaceuticals, INC. $253.43 2022-2025
E.R. Squibb & Sons, L.L.C. $207.41 2019-2024 Orencia
Ani Pharmaceuticals, INC. $192.78 2024-2025 Purified Cortrophin Gel, Sovuna
Genentech, INC. $159.80 2019
Mallinckrodt Enterprises LLC $137.36 2019
Si-Bone, INC. $127.71 2019
Sanofi-Aventis U.S. LLC $81.92 2019
Fresenius Kabi USA, LLC $77.03 2023 Idacio
Organon LLC $45.91 2023-2024 Hadlima
Depuy Synthes Sales INC. $45.20 2022-2023 Orthovisc
Pacira Therapeutics, INC. $39.83 2019
Teva Pharmaceuticals USA, INC. $28.78 2021-2022
Kiniksa Pharmaceuticals, Ltd. $27.66 2023 Arcalyst
Currax Pharmaceuticals LLC $27.29 2021
Pacira Pharmaceuticals Incorporated $26.84 2023 Iovera, Zilretta, Exparel
Arbor Pharmaceuticals, INC. $26.23 2019-2020
Fidia Pharma USA INC. $21.43 2019
Biocon Biologics INC $19.66 2024 Hulio
Tonix Medicines, INC. $18.80 2025 Tonmya
Ibsa Pharma INC. $15.89 2024 Tirosint, Licart
Vertical Pharmaceuticals, LLC $14.96 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $14.53 2025 Relistor
Mylan Institutional INC. $14.25 2023 Fulphila
Sobi, INC $13.47 2025
Ultragenyx Pharmaceutical INC. $12.00 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Knee

$19,938.45

in general payments reported 2019-2025

Years
2019-2025
Top company
Amgen INC.
Context
The $2,772 reported for 2025 was more than what 96% of providers received nationally.

https://glasscript.com/doctor/146146/michael-knee

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.